View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

ADMA Biologics Statement on Tariffs

ADMA Biologics Statement on Tariffs Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain RAMSEY, N.J. and BOCA RATON, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMA’s strategic advantage through fully U.S.-base...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: April 5, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: April 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of International Flavors & Fragrances, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 26 March 2025 in which we reassessed the appropriateness of the ra...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: April 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 8, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

International Flavors & Fragrances Inc: 1 director

A director at International Flavors & Fragrances Inc bought 6,500 shares at 80.436USD and the significance rating of the trade was 99/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...

 PRESS RELEASE

IFF Declares Dividend for First Quarter 2025

NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 11, 2025 to shareholders of record as of March 21, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at , , and...

 PRESS RELEASE

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial R...

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1) of $164.6 Million, a 309% YoY Increase FY 2024 Adjusted Net Income(2) of $119.2 Million, Compared to $0.7 Million in FY 2023, a 16,810% YoY Increase YE 2024 Total Cash Grew to More than $103 Million, Including $60 Million of Debt Organically Discharged During 2H 2024 ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

ADMA Biologics to Participate in the Raymond James Institutional Inves...

ADMA Biologics to Participate in the Raymond James Institutional Investor Conference RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 5, 2025, at 11:35 a.m. ET. A live audio webcast of the call will be available und...

 PRESS RELEASE

IFF Announces Expansion of Cedar Rapids, Iowa Ingredients Facility

NEW YORK--(BUSINESS WIRE)-- (NYSE: IFF) today unveiled plans to expand its Cedar Rapids, Iowa facility to capture a larger share of the booming healthy snacks market both in the U.S. and globally. The 47,000-square-foot expansion represents a nearly $70 million investment. When fully operational in the latter half of 2026, the expansion is projected to create up to 40 new jobs. “Our Cedar Rapids plant will be equipped with cutting-edge technologies, allowing us to provide U.S.-made fruit ingredients that can be easily integrated into food manufacturing processes,” said Andy Muller, preside...

 PRESS RELEASE

ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial R...

ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2024 financial results on March 3, 2025, after the U.S. financial markets close. ADMA’s management team will host a...

 PRESS RELEASE

IFF Announces Executive Leadership Team Aligned With New Operating Mod...

NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) announced changes to its executive leadership team, aligned with the Company’s external reporting structure. After 21 years of dedicated service to IFF, Simon Herriott, president of Health and Biosciences, will step down. Effective March 1, Leticia Gonçalves, ADM’s president of precision fermentation and ADM Ventures, will join IFF as president of Health and Biosciences. “Since 2019, Simon has driven growth and operational effectiveness through innovation, customer intimacy and supply chain development as president of our Health and Biosciences bus...

 PRESS RELEASE

IFF Reports Fourth Quarter and Full Year 2024 Results

NEW YORK--(BUSINESS WIRE)-- International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2024. Full year 2024 Consolidated Summary: Reported (GAAP)   Adjusted (Non-GAAP)1 Sales   Income Before Taxes   EPS   Operating EBITDA   Operating EBITDA Margin   EPS ex Amortization $11.5 B   $278 M   $0.95   $2.2 B   19.2%   $4.31 Management Commentary "IFF delivered a solid performance in 2024, reflecting the hard work and dedication of our gl...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch